Sanj K. Patel, President & CEO at SYNAGEVA BIOPHARMA CORP (GEVA), sold 70,000 shares at $40.48 ($2.8M) on 2013-06-12, disclosed to the SEC on 2013-06-13.
Scheduled sale ($2.8M) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $40.89 | 29,648 | $1.2M | 42.6% |
| 2 | $40.48 | 40,352 | $1.6M | 57.4% |
| Total | $40.65 avg | 70,000 | $2.8M | 100% |
| Filing → |
| KNSA | SELL | 2026-04-08 | $364K | — | Filing → |
| KNSA | SELL | 2025-10-22 | $20.0M | — | Filing → |
| KNSA | SELL | 2025-05-28 | $4.6M | — | Filing → |